A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Stopped This study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of IRR.

Conditions

• B-Cell Chronic Lymphocytic Leukemia

Interventions

• DRUG: Chlorambucil
• DRUG: Obinutuzumab
• DRUG: Placebo
• OTHER: Standard Premedication
• DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche